静脉注射费莫妥后淋巴系统的强化表现
研究纳入119例接受费莫妥增强三维血管成像的先天性心脏病连续患者,评估静脉注射费莫妥对T1加权和T2加权淋巴成像的影响;45例同时接受两种序列者中20例T1加权可见胸导管强化,镇静患者中仅2/26可见强化而非镇静患者18/19可见(P<0.001);结论认为费莫妥快速进入淋巴液,T2加权淋巴成像应在给药前完成。
要点
- T1加权成像上胸导管强化提示静脉注射费莫妥可快速进入淋巴液。
- 镇静与胸导管可见性降低强相关:镇静者2/26 vs 非镇静者18/19(P<0.001)。
- 给药后行T2加权成像胸导管不可见,淋巴评估应在费莫妥给药前完成。
核心结论
- T1加权成像上胸淋巴导管强化伴T2加权成像信号退化,提示静脉注射费莫妥快速进入淋巴液;为避免T2缩短降低成像质量,T2加权淋巴评估应在费莫妥给药前进行;镇静及由此推断的禁食可能影响该特性,需在未来研究中进一步探讨。
研究设计与样本
- 连续纳入接受费莫妥增强三维血管成像评估先天性心脏病的患者119例,平均年龄12.46岁±7.7岁;45例同时行T1加权和T2加权成像,另74例仅行T1加权成像;T1加权采用呼吸导航门控的三维反转恢复平衡稳态自由进动序列(常规用于血管成像),T2加权采用重T2加权快速自旋回波序列(用于淋巴成像);统计采用连续变量t检验和分类变量卡方检验。
关键影像表现/征象
- 45例同时行T1加权和T2加权成像者中,20例T1加权成像可见胸导管强化。
- 给药后行T2加权成像时,胸导管在T2加权图像上不可见。
- 全部45例胸导管可见者中,从给药到成像的时间范围为8分钟至75分钟。
局限性
- 镇静及由此推断的禁食可能影响该特性,需在未来研究中进一步探讨。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND: Lymphatic imaging is becoming increasingly important in the management of patients with congenital heart disease. However, the influence of the intravenous contrast agent ferumoxytol on lymphatic imaging is not well understood.
OBJECTIVE: To evaluate the impact of intravenous ferumoxytol on T1-weighted and T2-weighted lymphatic imaging in patients with congenital heart disease.
MATERIALS AND METHODS: We included consecutive patients receiving ferumoxytol-enhanced 3D angiography for congenital heart disease evaluation. The visibility of the thoracic duct was reviewed on the T1-weighted 3D inversion recovery balanced-steady-state free precession (SSFP) with respiratory navigator gating sequence which is routinely used for angiography and the heavily T2-weighted turbo spin echo sequence which is employed for lymphatic imaging. Data on demographics and time interval between contrast administration and imaging were collected. Statistical analyses were performed using t-tests for continuous variables and chi-squared tests for categorical variables.
RESULTS: One hundred nineteen consecutive patients with a mean age of 12.46 years±7.7 years were included. Of these, 45 cases underwent both T1-weighted and T2-weighted imaging; the other 74 underwent only T1-weighted imaging. Of the 45 patients, 20 had thoracic duct enhancement on T1-weighted imaging; among the 26 sedated, only 2 showed enhancement, while 18 of 19 non-sedated patients showed enhancement (P<0.001), indicating a strong association between sedation and reduced thoracic duct visibility. If T2-weighted imaging was performed after contrast administration, the thoracic duct was not visible on those images. For all 45 cases of visible thoracic duct in the entire cohort, the time from contrast administration to imaging ranged from 8 min up to 75 min.
CONCLUSION: The enhancement of the thoracic lymphatic duct on T1-weighted imaging, coupled with degradation observed on T2-weighted imaging, suggests that intravenously administered ferumoxytol rapidly enters the lymphatic fluid. To prevent T2 shortening from degrading the imaging results, T2-weighted imaging for lymphatic evaluation should be performed prior to the administration of ferumoxytol. Sedation and, by inference, fasting may influence this property and warrant further investigation in future studies.
引用
- Young DF, Reddy SV, Divekar A, et al. Enhancement of the lymphatic system following intravenous administration of ferumoxytol. Pediatr Radiol. 2024. PMID: 39382638. doi:10.1007/s00247-024-06061-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。